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Abstract. The purpose of this article is to investigate the performance of multivariate data analysis,
especially orthogonal partial least square (OPLS) analysis, as a semi-quantitative tool to evaluate the
comparability or equivalence of aerodynamic particle size distribution (APSD) profiles of orally inhaled
and nasal drug products (OINDP). Monte Carlo simulation was employed to reconstitute APSD profiles
based on 55 realistic scenarios proposed by the Product Quality Research Institute (PQRI) working
group. OPLS analyses with different data pretreatment methods were performed on each of the
reconstituted profiles. Compared to unit-variance scaling, equivalence determined based on OPLS
analysis with Pareto scaling was shown to be more consistent with the working group assessment. Chi-
square statistics was employed to compare the performance of OPLS analysis (Pareto scaling) with that
of the combination test (i.e., chi-square ratio statistics and population bioequivalence test for impactor-
sized mass) in terms of achieving greater consistency with the working group evaluation. A p value of
0.036 suggested that OPLS analysis with Pareto scaling may be more predictive than the combination test
with respect to consistency. Furthermore, OPLS analysis may also be employed to analyze part of the
APSD profiles that contribute to the calculation of the mass median aerodynamic diameter. Our results
show that OPLS analysis performed on partial deposition sites do not interfere with the performance on
all deposition sites.
KEY WORDS: aerodynamic particle size distribution; Monte Carlo simulation; multivariate data
analysis; orthogonal partial least square analysis.
INTRODUCTION
It is generally believed that aerosol particles greater than
10 µm in aerodynamic diameter deposit primarily in the head
and are swallowed subsequently rather than reaching the
lungs (1). Lung delivery requires particle size in the range of
1–5 µm (2–4), which deposit either centrally or peripherally in
the lungs depending on particle size. Therefore, aerodynamic
particle size distribution (APSD) is an important in vitro
characteristic of orally inhaled and nasal drug product
(OINDP) because of a plausible link between particle size
and eventual deposition in the respiratory tract. The interest
to develop a statistical method to determine in vitro
bioequivalence came from the practical need from both the
regulators and the drug manufacturer. Once innovator
companies make changes to a drug product or drug manu-
facturers plan to develop a generic version of a drug product,
evidence should be provided to the regulators that the new or
modified product has an APSD profiles sufficiently similar to
that of the original product.
The chi-square ratio statistic (5) proposed in the 1999 US
FDA guidance (6,7) was developed using Anderson eight-
stage cascade impactor (8) applied to albuterol metered-dose
inhaler data. In order to study this test’s applicability to a
broad range of OINDP profiles, a working group involving
scientists from industry, academia, FDA, and US pharmaco-
peia was established through the Product Quality Research
Institute (PQRI; 9). The working group expended a great
effort in investigating this chi-square ratio statistics. The work
began with developing a simulation method capable of
modeling APSD profiles and translating the chi-square ratio
statistics proposed by the FDA into an executable algorithm
(10). The working group first studied the stability of the chi-
square ratio test on pairs of identical profiles, which showed
that the stability increased as the number of stages increases
and less stable for profiles that are common to metered-dose
inhalers (MDIs) and dry powder inhalers (DPIs) (11). The
next study focused on pairs of profiles differing in a specified
and systematic way on a single deposition site, which gave rise
to a total number of 38 scenarios (11,12). The findings from
this study led the working group supplementing the chi-
square ratio statistics with a population bioequivalence (PBE)
test based on impactor-sized mass (ISM; 13) in order to
increase the discriminating ability of the overall statistical
procedure (14). Based on the study of this combination test (i.e.,
chi-square ratio test and ISM-PBE test), the working group
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produced a final report in 2007 on a statistical procedure for
determining equivalence (14). Due to the deficiencies of the
combination test, no recommendations were made by the
working group for APSD profiles comparison.
In this article, we proposed another method to evaluate
the comparability or equivalence of APSD profiles. The new
method is based on multivariate data analysis, especially
orthogonal partial least square (OPLS) analysis. Multivariate
data analysis can be generally divided into two categories
(15). One is the unsupervised method such as principal
component analysis. The other one is the supervised method
such as partial least square (PLS) analysis and orthogonal
partial least square analysis. Principal component analysis is
different from orthogonal partial least square analysis in that
a priori knowledge of the identity of the profiles was not
employed when patterns are assessed (15). Principal compo-
nent analysis is generally employed as a pattern recognition
tool before proceeding to the supervised method such as
OPLS. Orthogonal partial least square analysis relates a
matrix containing independent variables such as mass depo-
sition on each deposition site to a matrix containing depend-
ent variables such as profile membership in this case. OPLS
analysis is frequently employed as a discriminant analysis to
retrieve information lying in independent variables that may
result in class separation. However, the main objective of this
paper is not to use OPLS analysis to dissect out the
independent variables contributing to class separation.
Rather, the capability to detect difference between test and
reference profiles revealed by OPLS model fitting is our
primary goal. There are three reasons for proposing this
method: (1) an APSD profile contains information from
multiple deposition sites and therefore is a multivariate
measurement (1); (2) mass deposition on each stage is not
independent from each other. It has been suggested that the
deposition on different stages may co-vary between each
other (1) and this was indeed considered in the Monte Carlo
simulation of 55 realistic scenarios provided by the working
group (16,17); (3) principal components calculated in the
OPLS analysis are all orthogonal and thus can resolve the
issue of covariance (15). We began our work with first
reconstituting 55 realistic scenarios by Monte Carlo simu-
lation. Profiles generated were subjected to OPLS analysis to
derive a parameter Eq as described in the methods. Finally,
we compared the performance of the OPLS analysis with that
of the combination test in terms of achieving greater
consistency with the working group evaluation.
METHODS
Monte Carlo Simulation. Monte Carlo simulation was
performed in ADAPT II (University of Southern California)
to reconstitute 55 APSD profiles provided by the PQRI
working group (14,16,17). Information about the mean and
standard deviation for mass deposition on each site were
readily available from the profiles provided. They were used
as parameters for Monte Carlo simulation in ADAPT II.
Population simulation with output noise assuming normal
distribution of mass deposition on each stage was adopted.
Monte Carlo simulations with a number of 5,000 were
performed and repeated three times for each of the 55
realistic scenarios. The averages were taken for each scenario.
In some cases, simulations with different numbers were
performed for the purpose of demonstration. Data generated
were organized in Microsoft® Excel for each scenario.
Multivariate Data Analysis. OPLS analysis was carried
out in SIMCA-P 11.5 (Umetrics) and was employed to
compare test profiles with reference profiles in all scenarios.
Mass deposition data (X variables) were pretreated with
either Pareto scaling or unit-variance scaling in addition to
mean centering. Reference and test profiles are coded as 0
and 1 (Y variables) respectively. In order to normalize mass
deposition, absolute mass data were first normalized to
percent mass deposition data in Excel before proceeding to
OPLS analysis. The first two principal components are
calculated in all cases for the convenience of plotting.
However, the R2 for OPLS model fitting based on the first
principal component was recorded. Eq was defined as equal
to 1−R2 and served as a measure of equivalence between test
and reference profiles for all 55 scenarios.
Chi-square Test. Chi-square test was carried out in
Minitab 14.1 (Minitab Inc.) to compare OPLS analysis (with
Pareto scaling) with combination test proposed by the Food
and Drug Administration (FDA) and the PQRI working
group. The difference (Δ) between the working group
evaluation and Eq (by OPLS analysis) or proportion (by the
combination test) was divided into three categories: Δ≥0.5,
0.3≤Δ<0.5 and Δ<0.3. A p value less than 0.05 was
considered as statistically significant.
RESULTS AND DISCUSSION
Monte Carlo Simulation of 55 Realistic Scenarios
All 55 realistic scenarios have been simulated by Monte
Carlo simulation. Among these profiles, only two scenarios
were chosen to represent significant variability in the upper
deposition sites between test and reference profiles in
scenario 13c (Fig. 1a) as apposed to in the lower deposition
sites in scenario 2bb2 (Fig. 1b). Profiles simulated here are
slightly different in appearance from those provided by the
PQRI working group (14,16,17). This is possibly due to the
inherent variability of Monte Carlo simulation. A simulation
number of 30 was chosen for both scenarios.
Comparison of Chi-square Ratio Statistics and Orthogonal
Partial Least Square Analysis with Respect
to Profile Comparison
It was suggested that 30 reference and test inhalers
should be sampled individually and subject to chi-square ratio
statistics (1,11,14). A sample size of 30 was considered
necessary to represent the random sampling of a population
of dry powder inhalers or metered-dose inhalers manufac-
tured. In addition, this is also a practical number, which
requires a considerable yet manageable amount of sampling
work. Figure 2a shows the flowchart of the chi-square ratio
statistics. Thirty reference and test inhalers are randomly
sampled from corresponding populations (e.g., 5,000). Sample
profiles for these 30 inhalers are collected and then subject to
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chi-square ratio statistics. In an attempt to set up an appro-
priate critical value for chi-square ratio statistics, such
statistical testing based on 30 samples is repeated hundreds
of thousands of times to obtain a distribution of statistics,
upon which a reasonable critical value may be chosen. It
should be noted that the statistics obtained based on a sample
size of 30 actually gives the possibility of equivalence between
test and reference profiles from two corresponding popula-
tions rather than two samples. In contrast to chi-square ratio
statistics, Fig. 2b shows the rationale for OPLS analysis as an
analytical tool to judge equivalence between two populations.
First, it should be emphasized that the method developed
based on OPLS analysis is an analytical tool rather than a
statistical test. There is no p value associated with this
method. R2 or its derivative Eq was instead used as an
indicator of equivalence between test and reference profiles
(see explanation in the following section). This method also
begins with a random sampling of 30 samples consistent with
the chi-square ratio statistics. The sample mean and standard
deviation of mass at each deposition site was calculated based
on impactor data from these 30 samples. Rather than
statistical testing, the sample mean and standard deviation
was used for Monte Carlo simulation to obtain simulated
population profiles. Ideally, the population mean and
standard deviation of mass deposition should be used for
the population simulation. However, these numbers will not
be known until all the inhalers are characterized, which are
not practical. Therefore, we consider a sample size of 30 as
both necessary and practical since the more samples collected
the more accurately sample mean and standard deviation can
represent population mean and standard deviation. The size
for population simulation was also studied, which suggests
that a population size of 5,000 may be relevant and more
importantly the R2 based on this size tends to stabilize (data
Fig. 1. Reconstituted aerodynamic particle size distribution profiles
for scenario 13c and scenario 2bb2 (Monte Carlo simulations with a
number of 30 were generated for each reference and test profiles). a.
Scenario 13c. b. Scenario 2bb2
Fig. 2. Comparison of chi-square ratio statistics and orthogonal
partial least square analysis with respect to profile comparison. a.
Flowchart of the chi-square ratio statistics developed by the PQRI
working group. b. Flowchart of the orthogonal partial least square
analysis developed in our group
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not shown). Consequently, the R2 (or its derivative Eq) for
OPLS model fitting based on 5,000 profiles may serve as an
indicator of equivalence between test and reference popula-
tions of at least this size.
Orthogonal Partial Least Square Analysis of Test
and Reference Profiles
Profiles generated by Monte Carlo simulation were
analyzed by OPLS analysis as described in methods. OPLS
places the first principal component onto the largest differ-
ence between test and reference profiles. The successive
principal components will span the difference which is not
represented by the preceding component (15). Therefore,
OPLS score plot consisting of the first two components
provides a visual impression of the comparability between
test and reference profiles. The larger the difference between
the test and reference profiles, the further they are separated
from each other on the first principal component. However,
this separation is only a qualitative impression rather than a
quantitative measure. In order to derive a semi-quantitative
parameter which may serve as a measure of equivalence, R2
for OPLS model fitting (based on the first principal
component) was initially selected. R2 represents how well
the model fits the data or how much variability in the data can
be explained by the model (15). R2 equals to 0 if test and
reference profiles are identical; on the other hand, R2
approaches 1 when test profiles are completely different
from reference profiles assuming a right model is used. Apart
from model fitting, R2 also depends on the variability in the
Fig. 3. Score plot of orthogonal partial least square analysis to compare reference and test profiles generated by Monte
Carlo simulation (5,000). Each data point in the score plot represents a whole profile (deposition on all sites). Reference
profiles are colored blue and test profiles are colored red. a Reference profiles from scenario 1a were compared with itself
(two separate simulations). b–e Reference profiles were compared with test profiles from scenarios 1a, 1b, 1c, and 1d
respectively
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Table I. Equivalence Value Determined from Different Analysis Methods and the Working Group Evaluation
Scenario UV-Abs Par-Abs UV-Nor Par-Nor Chi-2+ISM WG
1a 0.64 0.73 0.68 0.77 0.70 1.00
1b 0.53 0.62 0.60 0.65 0.22 0.79
1c 0.34 0.46 0.42 0.47 0.01 0.07
1d 0.20 0.28 0.20 0.26 0.00 0.00
1aa 0.76 0.86 0.79 0.87 0.81 1.00
1bb 0.55 0.61 0.56 0.60 0.48 0.79
1cc 0.39 0.51 0.47 0.51 0.01 0.36
1dd 0.20 0.29 0.25 0.28 0.00 0.00
1ee 0.18 0.25 0.20 0.22 0.00 0.00
2a 0.67 0.74 0.68 0.78 0.89 0.79
2b 0.45 0.51 0.46 0.53 0.92 0.50
2c 0.43 0.46 0.44 0.47 0.89 0.21
2aa1 0.66 0.70 0.67 0.70 0.88 0.71
2bb1 0.47 0.51 0.49 0.60 0.80 0.64
2cc1 0.48 0.57 0.54 0.60 0.74 0.50
2dd1 0.46 0.55 0.48 0.54 0.89 0.29
2aa2 0.49 0.52 0.49 0.53 0.90 0.64
2bb2 0.48 0.51 0.49 0.52 0.89 0.29
2cc2 0.41 0.41 0.42 0.43 0.94 0.14
4a 0.90 0.93 0.91 0.94 0.88 1.00
4b 0.07 0.51 0.19 0.51 0.89 1.00
4c 0.08 0.26 0.11 0.26 0.68 0.21
4d 0.07 0.21 0.09 0.19 0.45 0.14
5a 0.72 0.78 0.74 0.80 0.89 0.93
5b 0.35 0.42 0.39 0.44 0.86 0.86
5c 0.12 0.16 0.15 0.16 0.50 0.29
7a 0.21 0.21 0.23 0.23 0.89 0.29
7b 0.44 0.48 0.49 0.53 0.95 0.50
7c 0.71 0.76 0.74 0.79 0.92 0.93
10a 0.18 0.17 0.17 0.16 1.00 0.14
10b 0.20 0.17 0.20 0.17 1.00 0.29
10c 0.41 0.41 0.41 0.41 1.00 0.50
10d 0.71 0.73 0.73 0.74 1.00 1.00
11a 0.36 0.39 0.49 0.51 0.78 0.64
11b 0.59 0.62 0.72 0.74 1.00 1.00
11c 0.82 0.84 0.83 0.87 1.00 1.00
12a0 0.05 0.06 0.05 0.06 0.07 0.07
12a1 0.07 0.09 0.07 0.10 0.82 0.14
12a2 0.10 0.15 0.10 0.16 1.00 0.86
12a3 0.12 0.27 0.13 0.29 1.00 1.00
12b0 0.11 0.16 0.11 0.17 0.03 0.29
12b1 0.17 0.26 0.19 0.31 0.93 0.86
12b2 0.25 0.44 0.27 0.47 1.00 0.86
12b3 0.31 0.55 0.33 0.56 1.00 1.00
13a 0.46 0.71 0.69 0.74 0.40 1.00
13b 0.29 0.60 0.43 0.65 0.38 0.57
13c 0.22 0.41 0.24 0.49 0.26 0.36
13d 0.12 0.38 0.29 0.43 0.00 0.21
13e 0.07 0.35 0.23 0.44 0.00 0.07
13f 0.38 0.87 0.50 0.90 0.84 0.93
13g 0.29 0.71 0.42 0.75 0.83 0.50
14a1 0.06 0.20 0.07 0.13 0.00 0.00
14a2 0.06 0.25 0.09 0.18 0.00 0.07
14a3 0.07 0.23 0.12 0.22 0.03 0.43
14a4 0.07 0.26 0.15 0.28 0.37 0.71
Column I: scenario ID. Columns II–V: equivalence (Eq value) determined based on orthogonal partial least square analysis with different data
pretreatment methods. Eq values in columns II–Vare the average of three individual simulations (n=3, 5,000 each). Column VI: likelihood of
equivalence based on the combination test proposed by the US FDA and the PQRI working group. Column VII: equivalence evaluated by the
working group. The likelihood of equivalence from the working group evaluation and the combination test were retrieved from Ref. (14)
UV-Abs absolute mass data were pretreated with unit-variance scaling, Par-Abs absolute mass data were pretreated with Pareto scaling, UV-
Nor normalized percent mass data were pretreated with unit-variance scaling, Par-Nor normalized percent mass data were pretreated with
Pareto scaling, Chi-2+ISM chi-square ratio statistics supplemented by a population bioequivalence test for impactor-sized mass, WG working
group evaluation
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data as will be seen in the following section where different
data pretreatment methods (i.e., different treatment of the
variability) were employed. Based on this rationale, we define
a parameter Eq=1−R2, which may be considered as a
measure of equivalence or comparability for the test and
reference profiles. Strictly speaking, Eq is not a statistical
value that can be used for statistical testing but rather a semi-
quantitative value defined by us for the purpose of
interpretive evaluation of APSD profiles.
Studying 55 Realistic Scenarios with Orthogonal Partial Least
Square Analysis
Based on the description above and in the methods,
OPLS analysis of 55 realistic scenarios was carried out with
different data pretreatment methods. The absolute mass
deposition data can be used as is or normalized to percent
mass deposition data. All the data were mean-centered to
avoid greater deposition on particular sites dominating the
whole distribution. To account for the variance on each
deposition site, in another word to weigh each site, two
scaling methods were employed. One is unit-variance (UV)
scaling in which the base weight is computed as the reciprocal
of standard deviation and the other is Pareto scaling which
gives the weight of the reciprocal of square root of
standard deviation (15). Pareto scaling is between no
scaling and UV scaling and gives the variable under
evaluation a variance equal to its standard deviation instead
of unit variance. The effect of both scaling methods was
investigated comprehensively.
Before performing OPLS analysis on all realistic scenar-
ios, we carried out a test analysis on the feasibility of this
method. In Fig. 3a, Monte Carlo simulations were performed
twice (5,000 for each) based on parameters from reference
profiles in scenario 1a. The first simulation generates 5,000
reference profiles and the second simulation generates
Fig. 4. Differences between the working group (WG) assessment and statistical analyses based on different methods and data pretreatment. a
Differences between the WG assessment and the combination test (chi-square plus ISM-PBE). b Differences between the WG assessment and
the OPLS analysis based on unit-variance scaling on absolute mass data. c Same as 4b except that Pareto scaling was used. d Same as 4b but
absolute mass data was first normalized to percent mass data. e Same as 4d but Pareto scaling was used. The working group evaluation and
possibility of equivalence from the combination test were retrieved from Ref. (14)
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another 5,000 reference profiles yet considered as test
profiles. Predictably, OPLS analysis on such reference and
test profiles should yield a R2 approaching 0 and both profiles
should be completely mixed without any separation on the
first principal component in the score plot. Indeed, we
observed the same phenomenon as shown in Fig. 3a. Then
OPLS analysis was performed for all realistic scenarios.
Figure 3b–e represents such analysis for scenario 1a–1d,
which was considered by the working group with decreasing
similarity between test and reference profiles. OPLS analysis
showed the same trend as evidenced by more and more
separation between profiles on the first principal component
in the score plot (Fig. 3b-e).
Effect of Different Data Pretreatment Methods
on the Performance of Orthogonal Partial Least
Square Analysis
The Eq value (defined as 1−R2) for each scenario
computed by OPLS analysis based on different data
pretreatment methods, the probability of equivalence
derived from the combination test (chi-square+ISM-PBE),
and the working group evaluation of equivalence are all
tabulated in Table I. It has been proposed by the working
group that agreement to within 50% (or 0.5) of the overall
frequency of equivalence declarations between the working
group and the combination test was interpreted as adequate
for the statistical procedure to make correct decisions (14). In
cases where the differences were more than 0.5, the
combination test was considered not be able to make the
correct decisions and inputs from reviews’ experience were
necessary to determine APSD equivalence. Similarly, we
extended this criterion to the performance of the OPLS
analysis (i.e., the difference between Eq value and the
working group assessment less than 0.5 was considered
adequate). The differences between the working group
evaluation and the combination test are plotted in Fig. 4a.
The difference between the working group assessment and
OPLS analysis for each of the data pretreatment methods are
plotted in Fig. 4b–e. We noticed that OPLS analysis with
Pareto scaling works better than UV scaling as evidenced by
less inconsistencies no matter whether absolute or normalized
mass was used. However, UV scaling on normalized mass
works better than the same scaling on absolute mass. The
effect of different scaling methods on multivariate data
analysis has been studied in other fields (18). Van de Berg
showed in his metabolomic study that Pareto scaling,
compared to unit-variance scaling, was more stable in terms
of generating reliable rank of the most important metabolites
(19). Noda examined two scaling techniques (Pareto scaling
vs. unit-variance scaling) to enhance two-dimensional
correlation Raman spectra and concluded that Pareto
scaling was able to circumvent the amplification of noise by
retaining a portion of magnitude information (20). Therefore,
it is not to our surprise that Pareto scaling works better than
UV scaling since the magnitude information about the mass
deposition on each site was retained. And this magnitude
information was not changed from absolute to normalized
mass deposition data when used with Pareto scaling.
However, the inaccuracy of mass deposition may be
amplified to a different extent with or without normalization
since the magnitude information was completely lost in unit-
variance scaling. This may provide a possible explanation for
the different performance on normalized or absolute mass
data with UV scaling. Finally, we compared (Fig. 5) the
performance of the combination test with that of OPLS
analysis based on Pareto scaling by chi-square statistical test
according to the criterion proposed in the methods. The p
value (0.036<0.05) suggested that multivariate data analysis
may be more indicative than the combination test for the
purpose of interpretive evaluation of comparability or
equivalence of APSD profiles.
Three Scenarios Mispredicted by Orthogonal Partial Least
Square Analysis
When OPLS analysis with Pareto Scaling was employed,
three scenarios with differences exceeding 0.5 are 12a2, 12a3,
and 12b1 (Fig. 4c and Table I). An impression of equivalent
test and reference profiles was given when these scenarios
were reconstituted by Monte Carlo simulation (data not
shown). However, OPLS analysis clearly separated the test
profiles from the reference profiles in the score plot (data not
shown) possibly because of very small standard deviation
relative to the mean in certain deposition sites. OPLS analysis
appeared to be sensitive to small standard deviation/mean
ratios while at this stage no efforts have been expended in
correlating the sensitivity of OPLS analysis to the standard
deviation/mean ratios. On the other hand, the combination
test predicts pretty well in these three scenarios (Fig. 4a and
Table I).
Orthogonal Partial Least Square Analysis of Mass Deposition
on Partial Deposition Sites
Comparison based on the whole deposition profiles was
recommended by the FDA and PQRI working group since a
change in mass deposition outside the impactor may affect the
Fig. 5. Comparison of the performance of the combination test (chi-
square plus ISM-PBE) with that of orthogonal partial least square
analysis based on Pareto scaling. The difference (Δ) between the
working group evaluation and each of the two analysis methods was
placed into three categories as labeled. The number of scenarios fall
into each category was plotted in the y axis and labeled above the
corresponding bar. Chi-square statistical test was then performed to
compare the two methods in terms of achieving greater consistencies
(Chi-Sq=6.632, p value=0.036). The working group assessment and
the possibility of equivalence from the combination test were
retrieved from Ref. (14)
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performance of the drug product (1). However, researchers
are sometimes interested in only a part of the APSD profiles
(e.g., mass deposition inside impactors and on the filter (21))
for two reasons: (1) there was no clear cut-off size for mass
deposition outside the impactor; (2) mass deposition on these
sites is important for the calculation of mass median
aerodynamic diameter. Therefore, we performed OPLS
analysis with Pareto scaling on mass deposition profiles inside
the impactor for all 55 realistic scenarios (data not shown).
Then, we compared the R2 obtained from partial deposition
sites with that from all deposition sites. In scenario 13c, the R2
for partial sites is 0.08 as opposed to 0.51 for all sites. This
difference may be explained by the greater difference
between test and reference profiles outside the impactor
while the difference inside the impactor is very small
(Fig. 1a). In scenario 2bb2, the major difference comes from
the deposition inside the impactor while little difference exists
outside the impactor. The R2 for partial sites is 0.46 and 0.48
for all sites. This modest increase in R2 is due to a mild
contribution of small difference from deposition sites outside
the impactor (Fig. 1b). Our analyses indicate that OPLS
analysis performed on partial deposition sites does not
interfere with the performance on all deposition sites.
CONCLUSION
Multivariate data analysis may open a new way for
scientists in the field of pharmaceutical aerosol sciences to
evaluate the comparability or equivalence of aerodynamic
particle size distribution profiles. Our study shows that
orthogonal partial least square analysis coupled with Pareto
scaling works best among all the data pretreatment methods
investigated. It is not the intention for this article to replace
the combination test proposed by the FDA and PQRI
working group; rather this new method may serve as a semi-
quantitative tool to evaluate particle size distribution profiles
before a robust and well-established statistical test can be
proposed. In addition, orthogonal partial least square analysis
should be performed with caution in certain situations where
the standard deviation/mean ratios are relatively small where
the combination test or more statistically relevant test should
be considered.
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